New drug batoclimab aims to reduce eye bulging in thyroid eye disease
NCT ID NCT05524571
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested whether batoclimab, an injected antibody, can reduce eye bulging (proptosis) in people with active, moderate-to-severe thyroid eye disease. 86 participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see how many people had at least a 2-millimeter reduction in eye protrusion without worsening in the other eye.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
batoclimab (a monoclonal antibody injection)
What this could lead to
If successful, batoclimab could offer a new treatment option to reduce eye bulging and inflammation in people with active thyroid eye disease.
What could go wrong
This is a relatively small Phase 3 trial (86 participants), and results may not apply to all patients. The drug may cause side effects or fail to show meaningful benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site Number - 1512
Winston-Salem, North Carolina, 27157, United States
-
Site Number - 1513
Rochester, Minnesota, 55905, United States
-
Site Number - 1518
Milwaukee, Wisconsin, 53226, United States
-
Site Number - 1521
Seattle, Washington, 98104, United States
-
Site Number - 1524
McAllen, Texas, 78503, United States
-
Site Number - 1525
Portland, Oregon, 97239, United States
-
Site Number - 1526
Livonia, Michigan, 48152, United States
-
Site Number - 3605
Barcelona, 08035, Spain
-
Site Number - 4672
Brussels, 1070, Belgium
-
Site Number - 4673
Brussels, 1200, Belgium
-
Site Number - 4674
Liège, 4000, Belgium
-
Site Number - 4950
Ankara, 6100, Turkey (Türkiye)
-
Site Number - 4951
Istanbul, 34010, Turkey (Türkiye)
-
Site Number - 4952
Adana, 13860, Turkey (Türkiye)
-
Site Number - 6603
Mainz, Rhineland-Palatinate, 55131, Germany
-
Site Number - 7550
Budapest, 1133, Hungary
-
Site Number - 7551
Pécs, 7621, Hungary
-
Site Number - 7552
Pécs, 7623, Hungary
-
Site Number - 7565
Sydney, 2000, Australia
-
Site Number - 7570
Christchurch, 8013, New Zealand
-
Site Number - 7572
Hamilton, 3204, New Zealand
-
Site Number - 9200
Bratislava, 82606, Slovakia
-
Site Number - 9201
Bratislava, 85107, Slovakia
-
Site Number - 9202
Trenčín, 91101, Slovakia
-
Site Number - 9203
Bratislava, 81108, Slovakia
-
Site Number - 9302
Ventspils, LV-3601, Latvia
-
Site Number -1510
Sarasota, Florida, 34239, United States
-
Site Number -1511
Morgantown, West Virginia, 26506, United States
-
Site Number -1514
Torrance, California, 90502, United States
-
Site Number -1515
Bellaire, Texas, 77401, United States
-
Site Number -1516
Louisville, Kentucky, 40202, United States
-
Site Number -1517
San Francisco, California, 94143, United States
-
Site Number -1519
San Antonio, Texas, 78215, United States
-
Site Number -1520
Pasadena, California, 91107, United States
-
Site Number -1990
San Juan, 00921, Puerto Rico
-
Site Number -3600
Santiago de Compostela, 15706, Spain
-
Site Number -3601
Madrid, 28007, Spain
-
Site Number -3602
Barcelona, 08006, Spain
-
Site Number -3603
Valencia, 46026, Spain
-
Site Number -3604
Madrid, 28034, Spain
-
Site Number -3606
Seville, 41009, Spain
-
Site Number -4670
Ghent, B-9000, Belgium
-
Site Number -4671
Bruges, 8000, Belgium
-
Site Number -9300
Riga, LV-1006, Latvia
-
Site Number -9301
Ogre, LV-5001, Latvia